CBD Global Sciences Performance
| CBDNFDelisted Stock | USD 0.06 0.00 0.00% |
The firm shows a Beta (market volatility) of -2.12, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning CBD Global are expected to decrease by larger amounts. On the other hand, during market turmoil, CBD Global is expected to outperform it. CBD Global Sciences at this moment shows a risk of 0.0%. Please confirm CBD Global Sciences standard deviation, potential upside, relative strength index, as well as the relationship between the jensen alpha and rate of daily change , to decide if CBD Global Sciences will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days CBD Global Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, CBD Global is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 541.00 | |
| Total Cashflows From Investing Activities | 220.5 K |
CBD |
CBD Global Relative Risk vs. Return Landscape
If you would invest 6.00 in CBD Global Sciences on August 26, 2024 and sell it today you would earn a total of 0.00 from holding CBD Global Sciences or generate 0.0% return on investment over 90 days. CBD Global Sciences is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than CBD, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
CBD Global Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CBD Global's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as CBD Global Sciences, and traders can use it to determine the average amount a CBD Global's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| CBDNF |
Based on monthly moving average CBD Global is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CBD Global by adding CBD Global to a well-diversified portfolio.
CBD Global Fundamentals Growth
CBD Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of CBD Global, and CBD Global fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CBD Pink Sheet performance.
| Return On Asset | -1.38 | |||
| Operating Margin | (2.71) % | |||
| Current Valuation | 14.44 M | |||
| Shares Outstanding | 49.46 M | |||
| Price To Sales | 2.79 X | |||
| Revenue | 166.95 K | |||
| EBITDA | (4.6 M) | |||
| Cash And Equivalents | 59.92 K | |||
| Total Debt | 1.34 M | |||
| Book Value Per Share | (0.26) X | |||
| Cash Flow From Operations | (1.14 M) | |||
| Earnings Per Share | (0.11) X | |||
| Total Asset | 2.09 M | |||
About CBD Global Performance
By analyzing CBD Global's fundamental ratios, stakeholders can gain valuable insights into CBD Global's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CBD Global has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CBD Global has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
CBD Global Sciences Inc. engages in cannabidiol farming, processing, and product manufacturing business. The company was incorporated in 2018 and is headquartered in Lakewood, Colorado. Cbd Global operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.Things to note about CBD Global Sciences performance evaluation
Checking the ongoing alerts about CBD Global for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for CBD Global Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CBD Global Sciences is not yet fully synchronised with the market data | |
| CBD Global Sciences has some characteristics of a very speculative penny stock | |
| CBD Global Sciences has a very high chance of going through financial distress in the upcoming years | |
| CBD Global Sciences has accumulated 1.34 M in total debt. CBD Global Sciences has a current ratio of 0.09, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist CBD Global until it has trouble settling it off, either with new capital or with free cash flow. So, CBD Global's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CBD Global Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CBD to invest in growth at high rates of return. When we think about CBD Global's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 166.95 K. Net Loss for the year was (5.25 M) with profit before overhead, payroll, taxes, and interest of 3.61 K. | |
| CBD Global Sciences has accumulated about 59.92 K in cash with (1.14 M) of positive cash flow from operations. | |
| Roughly 27.0% of the company shares are held by company insiders |
- Analyzing CBD Global's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CBD Global's stock is overvalued or undervalued compared to its peers.
- Examining CBD Global's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CBD Global's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CBD Global's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CBD Global's pink sheet. These opinions can provide insight into CBD Global's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in CBD Pink Sheet
If you are still planning to invest in CBD Global Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CBD Global's history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |